Akèy › Artrit jivenil
Etid klinik pou Artrit jivenil ap rekrite nan Etazini
17 etid pou Artrit jivenil ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Washington, DC6 etid
- Cincinnati, OH6 etid
- Portland, OR5 etid
- New York City, NY4 etid
- Pittsburgh, PA4 etid
- Salt Lake City, UT4 etid
- Cleveland, OH3 etid
- Gainesville, FL3 etid
- Indianapolis, IN3 etid
Pa eta
- Distrik Columbia4 etid
- Florid4 etid
- Indiana3 etid
- Kalifòni3 etid
- New York5 etid
- North Carolina3 etid
- Ohio8 etid
- Oregon5 etid
- Pennsylvania4 etid
- Texas4 etid
- Utah4 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Natural History and Development of Spondyloarthritis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 2 a 99 · Tout sèks · Mizajou Oct 2, 2026 · NCT01422694Allogeneic Hematopoietic Cell Transplantation for Refractory Systemic Juvenile Idiopathic Arthritis.
Ap rekriteEtid obsèvasyon
Jiska laj 35 · Tout sèks · Mizajou Sep 29, 2026 · NCT07845942Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
Ap rekriteFaz 1
Laj 2 a 17 · Tout sèks · Mizajou Sep 28, 2026 · NCT06751238A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
Ap rekriteFaz 2
Laj 1 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07203001Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis
Ap rekriteFaz 3
Laj 2 a 21 · Tout sèks · Mizajou Sep 25, 2026 · NCT06654882A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Ap rekriteFaz 3
Laj 3 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06663332Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
Ap rekriteFaz 3
Laj 1 a 17 · Tout sèks · Mizajou Sep 15, 2026 · NCT05609630Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Tout sèks · Mizajou Sep 10, 2026 · NCT06339177A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
Ap rekriteFaz 3
Laj 5 a 17 · Tout sèks · Mizajou Sep 1, 2026 · NCT06100744Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
Ap rekriteEtid obsèvasyon
Jiska laj 21 · Tout sèks · Mizajou Aug 27, 2026 · NCT02418442Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions
Ap rekriteEtid obsèvasyon
Laj 5 a 21 · Tout sèks · Mizajou Jul 24, 2026 · NCT04833465Pain in Juvenile Arthritis
Ap rekriteVolontè an sante akeyi
Laj 9 a 17 · Tout sèks · Mizajou Jul 14, 2026 · NCT07217782Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 9, 2026 · NCT07138898The BRIDGE Pain Study
Ap rekriteEtid obsèvasyon
Laj 14 a 26 · Tout sèks · Mizajou May 22, 2026 · NCT07602595Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 2 ak plis · Tout sèks · Mizajou Jan 22, 2026 · NCT04806620Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
Ap rekriteFaz 2
2 Months – 55 Years · Tout sèks · Mizajou Dec 15, 2025 · NCT01962415Quantification & Classification of Inflammatory Cells in Uveitis Using OCT
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 5 a 85 · Tout sèks · Mizajou Jul 17, 2025 · NCT07065747Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.